Key facts
- iQure Pharma’s last known valuation is $21.0M (Nov 2025).
- It has raised $13.1M across 4 recorded rounds; the latest was Seed Round ($650K) in May 2026.
- Notable investors include Keiretsu Forum, Endless Frontier Labs, SideCar Angels, Accelerator Venture Partners, Mass Medical Angels — 8 tracked in total.
- iQure Pharma has filed 3 Form Ds with the SEC since 2023, most recently Jan 2025 ($1.4M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for iQure Pharma
Funding rounds
4 roundsAbout iQure Pharma
Developer of biopharmaceutical therapies designed to address central nervous system disorders by restoring glutamate homeostasis. The company focuses on enhancing astrocytic regulation of glutamate uptake to maintain synaptic balance and protect neurons from overstimulation, enabling the prevention of excitotoxicity-driven neuronal damage and disease progression across a broad range of neurological conditions.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2019
- Employees
- 8
- Website
- iqurepharma.com/
- Ownership
- Privately Held (backing)
iQure Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iQure Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iQure Pharma in its N-PORT filings yet. We sweep new filings monthly.